首页> 外文期刊>Liver international >Hepatitis delta infection among persons living with HIV in Europe
【24h】

Hepatitis delta infection among persons living with HIV in Europe

机译:欧洲艾滋病毒感染者中的德尔塔型肝炎感染

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Background and Aims A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes. Methods All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti‐HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV‐positive and HDV‐negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver‐related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause‐specific multivariable Cox regression. Results Of 2793 HBsAg‐positive participants, 1556 (56) had stored serum available and were included. The prevalence of HDV coinfection was 15.2 (237/1556, 95 confidence interval CI: 13.5–17.1) and 66 (132/200) of HDV‐positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5 (182/360, 95 CI: 45.3–55.7), with similar estimates across Europe, compared to 4.7 (52/1109, 95 CI: 3.5–5.9) among other participants. During a median follow‐up of 10.8?years (interquartile range 5.6–17.8), 82 (34.6) HDV‐positive and 265 (20.1) HDV‐negative individuals died. 41.5 (34/82) of deaths were liver‐related in HDV‐positive individuals compared to 17.7 (47/265) in HDV‐negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95 CI 1.2–2.1), liver‐related death (2.9, 1.6–5.0) and HCC (6.3, 2.5–16.0). Conclusion We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from populations without HIV. HDV coinfection was associated with liver‐related mortality and HCC incidence.
机译:摘要 背景和目的 据报道,欧洲艾滋病毒感染者(PLWH)中德尔塔病毒(HDV)感染率很高,这是最严重的病毒性肝炎。我们分析了来自大型HIV队列合作的数据,以描述整个欧洲的HDV流行病学趋势及其对临床结局的影响。方法 对 1988 年至 2019 年间瑞士 HIV 队列研究和 EuroSIDA 中所有乙型肝炎表面抗原 (HBsAg) 阳性的 PLWH 进行抗 HDV 抗体检测,如果阳性,则检测 HDV RNA。使用描述性统计比较了 HDV 阳性和 HDV 阴性个体开始抗逆转录病毒治疗时的人口统计学和临床特征。使用累积发病率图和特定原因多变量 Cox 回归评估 HDV 感染与总死亡率、肝脏相关死亡率以及肝细胞癌 (HCC) 之间的关联。结果 2793例HBsAg阳性受试者中,1556例(56%)储存了可用血清并被纳入。丁型肝炎病毒合并感染的患病率为 15.2%(237/1556,95% 置信区间 [CI]:13.5%–17.1%),66% (132/200) 的丁型肝炎病毒阳性个体具有活动性丁型肝炎病毒复制。在注射吸毒者(PWID)中,丁型肝炎病毒合并感染的患病率为50.5%(182/360,95%CI:45.3%-55.7%),整个欧洲的估计值相似,而其他参与者的估计值为4.7%(52/1109,95%CI:3.5%-5.9%)。在中位随访 10 次期间。8?年(四分位距5.6-17.8),82例(34.6%)HDV阳性和265例(20.1%)HDV阴性个体死亡。在HDV阳性个体中,41.5%(34/82)的死亡与肝脏有关,而HDV阴性个体的死亡为17.7%(47/265)。丁型肝炎病毒感染与总死亡率(校正风险比 1.6;95% CI 1.2-2.1)、肝脏相关死亡 (2.9、1.6-5.0)和肝细胞癌 (6.3、2.5-16.0) 相关。结论 我们发现整个欧洲的 PWID 中 delta 肝炎患病率非常高。在不注射毒品的PLWH中,患病率与未感染艾滋病毒的人群报告的患病率相似。丁型肝炎病毒合并感染与肝脏相关死亡率和肝细胞癌发病率相关。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号